Daphne Karydas - 19 Feb 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
19 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 19:47:24 UTC
Previous filing
13 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Karydas Daphne Director 150 N. RADNOR CHESTER RD., SUITE F200, RADNOR /s/ Adam Levy, Attorney-in-fact 20 Feb 2026 0001816952

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Award $0 +6,200 $0.000000 6,200 19 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Award $0 +8,300 $0.000000 8,300 19 Feb 2026 Common Stock 8,300 $28.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
F2 The stock option vests in 12 substantially equal monthly installments following the date of grant.